Interleukin-17: The missing link between T-cell accumulation and effector cell actions in rheumatoid arthritis?

Immunology and Cell Biology

Volumn 82, Issue 1, 2004, Pages 1-9

  Stamp, Lisa K ^a   James, Michael J ^a   Cleland, Leslie G ^a  

^a ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Interleukin 17; Rheumatoid arthritis; T cells

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYTOTOXIC T LYMPHOCYTE ANTIGEN 8; ICOSANOID; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; MATRIX METALLOPROTEINASE; MONOKINE; OSTEOCLAST DIFFERENTIATION FACTOR; PROSTAGLANDIN E2; PROTEOGLYCAN; T LYMPHOCYTE ANTIGEN; THROMBOXANE A2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

BORRELIA BURGDORFERI; CARTILAGE DEGENERATION; CONTROLLED STUDY; CYTOKINE RELEASE; EFFECTOR CELL; HUMAN; HUMAN CELL; ICOSANOID METABOLISM; MACROPHAGE; MONOCYTE; NEUTROPHIL; OSTEOCLAST; OSTEOLYSIS; PROTEOGLYCAN SYNTHESIS; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIAL FLUID; SYNOVIUM; T LYMPHOCYTE; TRANSGENE;

ANIMALS; ARTHRITIS, RHEUMATOID; HUMANS; INTERLEUKIN-17; MACROPHAGES; RECEPTORS, INTERLEUKIN; T-LYMPHOCYTES;

ANIMALIA; BORRELIA; BORRELIA BURGDORFERI;

EID: 1642317684     PISSN: 08189641     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1711.2004.01212.x     Document Type: Review

References (88)

1. Broxmeyer H. Is interleukin-17, an inducible cytokine that stimulates production of other cytokines, merely a redundant player in a sea of other biomolecules. J. Exp. Med. 1996; 183: 2411-5.
2. Katz Y, Nadiv O. Interleukin-17 may have a central role in inflammatory joint disease as a 'fine-tuning' cytokine. Israel Med. Assoc. J. 2000; 2: 21-2.
3. Rouvier E, Luciani M, Mattei M, Denizot F, Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a Herpesvirus Saimiri gene. J. Immunol. 1993; 150: 5445-56.
4. Caput D, Beutler B, Hartog K, Thayer R, Brown-Shimer S, Cerami A. Identification of a common nucleotide sequence in the 3′-untranslated region of mRNA molecules specifying inflammatory mediators. Proc. Natl Acad. Sci. USA 1986; 83: 1670-4.
5. Shaw G, Kamen R. A conserved AU sequence from the 3′ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell 1986; 46: 659-67.
6. Yao Z, Fanslow WC, Seldin MF et al. Herpesvirus Saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995; 3: 811-21.
7. Yao Z, Painter SL, Fanslow WC et al. Human IL-17: a novel cytokine derived from T cells. J. Immunol. 1995; 155: 5483-6.
8. Fossiez F, Djossou O, Chomarat P et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 1996; 183: 2593-603.
9. Lenarczyk A, Helsloot J, Farmer K, Peters L, Sturgess A, Kirkham BW. Antigen induced IL-17 response in the peripheral blood mononuclear cells (PBMC) of healthy controls. Clin. Exp. Immunol. 2000; 122: 41-8.
10. Albanesi C, Cavani A, Girolomoni G. IL-17 is produced by nickel-specific T lymphocytes and regulates ICAM-1 expression and chemokine production in human keratinocytes. Synergistic or antagonist effects with IFN-γ and TNF-α. J. Immunol. 1999; 162: 494-502.
11. + T cells by cyclic AMP-dependent signal transduction pathway. Cytokine 1998; 10: 841-50.
12. Aggarwal S, Ghilardi N, Xie M-H, de Sauvage F, Gurney A. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 2003; 278: 1910-4.
13. Infante-Duarte C, Horton H, Byrne M, Kamradt T. Microbial lipopeptides induce the production of IL-17 in Th cells. J. Immunol. 2000; 165: 6107-15.
14. + T cell subset with an unrestricted cytokine profile. J. Immunol. 1989; 143: 518-25.
15. Romagnani S. The Th1/Th2 paradigm. Immunol. Today 1997; 18: 263-6.
16. Albanesi C, Scarponi C, Cavani A, Federici M, Nasorri F, Girolomoni G. Interleukin 17 is produced by both Th1 and Th2 lymphocytes and modulates interferon-γ and interleukin-4 induced activation of human keratinocytes. J. Invest. Derm. 2000; 115: 81-7.
17. Aarvak T, Chabaud M, Miossec P, Natvig JB. IL-17 is produced by some proinflammatory Th1/Th0 cells but not by Th2 cells. J. Immunol. 1999; 162: 1246-51.
18. Yao Z, Spriggs MK, Derry J et al. Molecular characterization of the human interleukin (IL) -17 receptor. Cytokine 1997; 9: 794-800.
19. Shalom-Barak T, Quach J, Lotz M. Interleukin-17-induced gene expression in articular chondrocytes is associated with activation of mitogen-activated protein kinases and NF-κB. J. Biol. Chem. 1998; 273: 27467-73.
20. Martel-Pelletier J, Mineau F, Jovanovic D, Di Battista J, Pelletier J. Mitogen-activated protein kinase and nuclear factor κB together regulate interleukin-17-induced nitric oxide production in human osteoarthritic chondrocytes. Arthritis Rheum. 1999; 42: 2399-409.
21. Awane M, Andres P, Li D, Reinecker HC. NF-κB inducing kinase is a common mediator of IL-17-, TNF-α-, and IL-1β-induced chemokine promoter activation in intestinal epithelial cells. J. Immunol. 1999; 162: 5337-44.
22. Andoh A, Takaya H, Makino J et al. Cooperation of interleukin-17 and interferon-γ on chemokine secretion in human fetal intestinal epithelial cells. Clin. Exp. Immunol. 2001; 125: 56-63.
23. Hata K, Andoh A, Shimada M et al. IL-17 stimulates inflammatory responses via NF-κB and MAP kinase pathways in human colonie myofibroblasts. Am. J. Physiol. Gastrointest. Liver Physiol. 2002; 282: G1035-G44.
24. Schwandner R, Yamaguchi K, Cao Z. Requirement of tumour necrosis factor receptor-associated factor (TRAF) 6 in interleukin 17 signal transduction. J. Exp. Med. 2000; 191: 1233-9.
25. Subramaniam SV, Cooper RS, Adunyah SE. Evidence for the involvement of JAK/STAT pathway in the signaling mechanism of interleukin-17. Biochem. Biophys. Res. Comm. 1999; 262: 14-9.
26. Kotake S, Udagawa N, Takahashi N et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J. Clin. Invest. 1999; 103: 1345-52.
27. Chabaud M, Durand JM, Buchs N et al. Human Interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. Arthritis Rheum. 1999; 42: 963-70.
28. Ziolkowska M, Koc A, Luszczykiewics G et al. High levels of IL-17 in rheumatoid arthritis patients: IL-15 triggers in vitro IL-17 production via cyclosporin A-sensitive mechanism. J. Immunol. 2000; 164: 2832-8.
29. Fujino S, Andoh A, Bamba S et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 2003; 52: 65-70.
30. Teunissen M, Koomen C, de Waal Malefyt R., Wierenga E, Bos J. Interleukin-17 and interferon-γ synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J. Invest. Derm. 1998; 111: 645-9.
31. Antonysamy M, Fanslow WC, Fu F et al. Evidence for a role of IL-17 in organ allograft rejection: IL-17 promotes the functional differentiation of dendritic cell progenitors. J. Immunol. 1999; 162: 577-84.
32. Loong C, Hsieh H, Lui W, Chen A, Lin C. Evidence for early involvement of interleukin 17 in human and experimental renal allograft rejection. J. Pathol. 2002; 197: 322-32.
33. Kostulas N, Pelidou S, Kivisakk P, Kostulas P, Link H. Increased IL-1β, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischaemic stroke study. Stroke 1999; 30: 2174-9.
34. Firestein G, Alvaro-Garcia J, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J. Immunol. 1990; 144: 3347-53.
35. Simon AK, Seipelt E, Sieper J. Divergent T-cell cytokine patterns in inflammatory arthritis. Proc. Natl Acad. Sci. USA 1994; 91: 8562-6.
36. Ulfgren AK, Lindbald S, Klareskog L, Andersson J, Andersson U. Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis. Ann. Rheum. Dis. 1995; 54: 654-61.
37. Dolhain R, van den Heiden A, ter Haar N, Breedveld FC, Miltenburg A. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum. 1996; 39: 1961-9.
38. Barnes P, Fong S-J, Brennan P, Twomey P, Mazumder A, Modlin R Local production of tumour necrosis factor and IFN-γ in tuberculous pleuritis. J. Immunol. 1990; 145: 149-54.
39. Dolhain R, Ter Haar N, Hoefakker S et al. Increased expression of interferon (IFN) -gamma together with IFN-gamma receptor in the rheumatoid synovial membrane compared with synovium of patients with osteoarthritis. Br. J. Rheum. 1996; 35: 24-32.
40. van Roon JA, Lafeber FPJG, Bijlsma JWJ. Synergistic activity of interleukin-4 and interleukin-10 suppression of inflammation and joint destruction in rheumatoid arthritis. Arthritis Rheum. 2001; 44: 3-12.
41. Woods J, Haines G, Shah M, Koch A. Low-level production of interleukin-13 in synovial fluid and tissue from patients with arthritis. Clin. Immunol. Immunopath. 1997; 85: 210-20.
42. Burmeister G-R, Stuhlmuller B, Keyszer G, Kinne R. Mononuclear phagocytes and rheumatoid synovitis. Mastermind or workhorse in arthritis? Arthritis Rheum. 1997; 40: 5-18.
43. Firestein GS, Zvaifler NJ. How important are T cells in chronic rheumatoid synovitis? Arthritis Rheum. 1990; 33: 768-73.
44. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 1994; 76: 301-14.
45. Honorati MC, Meliconi R, Pulsatelli L, Cane S, Frizziero L, Facchini A. High in vivo expression of interleukin-17 receptor in synovial endothelial cells and chondrocytes from arthritis patients. Rheumatology 2001; 40: 522-7.
46. Modlin R, Melancon-Kaplan J, Young S et al. Learning from lesions: patterns of tissue inflammation in leprosy. Proc. Natl Acad. Sci. USA 1988; 85: 1213-7.
47. Nakae S, Komiyama Y, Nambu A et al. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 2002; 17: 375-87.
48. Kehlen A, Thiele K, Riemann D, Langner J. Expression, modulation and signaling of IL-17 receptor in fibroblast-like synoviocytes of patients with rheumatoid arthritis. Clin. Exp. Immunol. 2002; 127: 539-46.
49. Burger D, Rezzonico R, Li J et al. Imbalance between interstitial collagenase and tissue inhibitor of metalloproteinases 1 in synoviocytes and fibroblasts upon direct contact with stimulated T lymphocytes. Arthritis Rheum. 1998; 41: 1748-59.
50. Bombara MP, Webb DL, Conrad P et al. Cell contact between T cells and synovial fibroblasts causes induction of adhesion molecules and cytokines. J. Leukoc. Biol. 1993; 54: 399-406.
51. Thiele K, Riemann D, Santos AN, Langner J, Kehlen A. Cell-cell contact of human T cells with fibroblasts changes lymphocytic mRNA expression: increased mRNA expression of interleukin-17 and interleukin-17 receptor. Eur. Cytokine Netw. 2000; 11: 53-8.
52. Pillinger MH, Abramson SB. The neutrophil in rheumatoid arthritis. Rheum. Dis. Clin. North Am. 1995; 21: 691-715.
53. Laan M, Cui Z, Hoshina H et al. Neutrophil recruitment by human IL-17 via C-X-C chemokine release in the airways. J. Immunol. 1999; 162: 2347-52.
54. Laan M, Lotvall J, Chung KF, Linden A. IL-17 induced cytokine release in human bronchial epithelial cells in vitro: role of mitogen-activated protein (MAP) kinases. Br. J. Pharmacol. 2001; 133: 200-8.
55. Arend WP, Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumour necrosis factor α in rheumatoid arthritis. Arthritis Rheum. 1995; 38: 151-60.
56. Badolato R, Oppenheim JJ. Role of cytokines, acute phase proteins and chemokines in the progression of rheumatoid arthritis. Semin. Arthritis Rheum. 1996; 26: 526-38.
57. Brennan FM, Maini RN, Feldmann M. TNFα - a pivotal role in rheumatoid arthritis? Br. J. Rheum. 1992; 31: 293-8.
58. Arend WP, Dayer J-M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. 1990; 33: 305-15.
59. Dinarello CA, Moldawer L. 2000 Proinflammatory and antiinflammatory cytokines in rheumatoid arthritis. A Primer for Clinicians, 2nd edn, p. 282. Amgen, Thousand Oaks.
60. 2 blocks inflammation, hyperalgesia and interleukin 6 production in vivo. J. Exp. Med. 1996; 184: 883-91.
61. 2 in nonadherent human monocytes. J. Immunol. 1997; 158: 351-8.
62. Chabaud M, Fossiez F, Taupin J-L, Miossec P. Enhancing effect of IL-17 on IL-1-induced IL-6 and leukaemia inhibitory factor production by rheumatoid arthritis synoviocytes and its regulation by Th2 cytokines. J. Immunol. 1998; 161: 409-14.
63. Katz Y, Nadiv O, Beer Y. Interleukin-17 enhances tumour necrosis factor α - induced synthesis of interleukins 1, 6, and 8 in skin and synovial fibroblasts. Arthritis Rheum. 2001; 44: 2176-84.
64. 2 production in explants of human osteoarthritic knee menisci. Arthritis Rheum. 2001; 44: 2078-83.
65. Koshy PJ, Henderson N, Logan C, Life P, Cawston T, Rowan A. Interleukin 17 induces cartilage breakdown: novel synergistic effects in combination with proinflammatory cytokines. Ann. Rheum. Dis. 2002; 61: 704-13.
66. Chabaud M, Lubberts E, Joosten L, van den Berg W, Miossec P. IL-17 derived from juxta-articular bone and synovium contributes to joint degradation in rheumatoid arthritis. Arthritis Res. 2001; 3: 168-77.
67. Dudler J, Renggli-Zulliger N, Busso N, Lotz M, So A. Effect of interleukin 17 on proteoglycan degradation in murine knee joints. Ann. Rheum. Dis. 2000; 59: 529-32.
68. Lubberts E, Joosten L, Oppers B et al. IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis. J. Immunol. 2001; 167: 1004-13.
69. Lubberts E, Joosten L, van de Loo F, Schwarzenberger P, Kolls J, van den Berg W. Overexpression of IL-17 in the knee joint of collagen type II immunized mice promotes collagen arthritis and aggravates joint destruction. Inflamm. Res. 2002; 51: 102-4.
70. Bush KA, Farmer KM, Walker JS, Kirkham BW. Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. Arthritis Rheum. 2002; 46: 802-5.
71. Jovanovic D, Martel-Pelletier J, Di Battista J et al. Stimulation of 92-kd gelatinase (matrix metalloproteinase 9) production by interleukin-17 in human monocyte/macrophages. Arthritis Rheum. 2000; 43: 1134-44.
72. 2 in interleukin 17 stimulated human monocytes/macrophages. J. Rheum. 2001; 28: 712-8.
73. Chabaud M, Garnero P, Dayer J-M, Guerne P, Fossiez F, Miossec P. Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. Cytokine 2000; 12: 1092-9.
74. Lubberts E, Joosten L, van de Loo F, van den Bersselaar L, van den Berg W. Reduction of interleukin-17-induced inhibition of chondrocyte proteoglycan synthesis in intact murine articular cartilage by interleukin-4. Arthritis Rheum. 2000; 43: 1300-6.
75. Van Bezooijen RL, van der Wee-Pals L, Papapoulos SE, Lowik CW. Interleukin 17 synergises with tumour necrosis factor α to induce cartilage destruction in vitro. Ann. Rheum. Dis. 2002; 61: 870-6.
76. Taskiran D, Stefanovic-Racic M, Georgescu H, Evans C. Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1. Biochem. Biophys. Res. Comm. 1994; 200: 142-8.
77. Murrell G, Jang D, Williams RJ. Nitric oxide activates metalloproteinase enzymes in articular cartilage. Biochem. Biophys. Res. Comm. 1995; 206: 15-21.
78. Cao M, Westerhausen-Larson A, Niyibizi C et al. Nitric oxide inhibits the synthesis of type-II collagen without altering CoI2A1 mRNA abundance: prolyl hydroxylase as a possible target. Biochem. J. 1997; 324: 305-10.
79. Clancy R, Amin A, Abramson S. The role of nitric oxide in inflammation and immunity. Arthritis Rheum. 1998; 41: 1141-51.
80. Attur M, Patel R, Abramson S, Amin A. Interleukin-17 upregulation of nitric oxide production in human osteoarthritis cartilage. Arthritis Rheum. 1997; 40: 1050-3.
81. Pacquelet S, Presle N, Boileau C et al. Interleukin 17, a nitric oxide-producing cytokine with a peroxynitrite-independent inhibitory effect on proteoglycan synthesis. J. Rheum. 2002; 29: 2602-10.
82. Van Bezooijen RL, Farih-Sips H, Papapoulos SE, Lowik CW. Interleukin-17: a new bone acting cytokine in vitro. J. Bone Min. Res. 1999; 14: 1513-21.
83. Van Bezooijen RL, Papapoulos SE, Lowik CW. Effect of interleukin-17 on nitric oxide production and osteoclastic bone resorption: is there dependency on nuclear factor-κB and receptor activator of nuclear factor κB (RANK)/RANK ligand signaling? Bone 2001; 28: 378-86.
84. Lubberts E, Van Den Bersselaar L, Oppers-Walgreen B et al. IL-17 promotes bone erosion in murine collagen induced arthritis through loss of the receptor activator of NF-κB ligand/osteoprotegerin balance. J. Immunol. 2003; 170: 2655-62.
85. Chabaud M, Miossec P. The combination of tumour necrosis factor-α blockade with interleukin-1 and interleukin-17 blockade is more effective for controlling synovial inflammation and bone resorption in an ex vivo model. Arthritis Rheum. 2001; 44: 1293-303.
86. Chevrel G, Garnero P, Miossec P. Addition of interleukin-1 (IL-1) and IL-17 soluble receptors to a tumour necrosis factor α soluble receptor more effectively reduces the production of IL-6 and macrophage inhibitory protein-3α and increases that of collagen in an in vitro model of rheumatoid synoviocyte activation. Ann. Rheum. Dis. 2002; 61: 730-3.
87. O'Dell J, Haire C, Erikson N et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine or a combination of all three medications. N. Engl. J. Med. 1996; 334: 1287-91.
88. Jovanovic D, Di Battista J, Martel-Pelletier J et al. IL-17 stimulates the production and expression of proinflammatory cytokines, IL-β and TNF-α by human macrophages. J. Immunol. 1998; 160: 3513-21.